Chronic Myeloid Leukemia: A Historical Perspective

Seminars in Hematology

Volumn 47, Issue 4, 2010, Pages 302-311

  Goldman, John M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; ARSENIC; BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; BUSULFAN; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEPRESSION; DONOR LYMPHOCYTE INFUSION; DONOR SELECTION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; HISTORY OF MEDICINE; HLA MATCHING; HUMAN; HYPOGONADISM; INSOMNIA; LETHARGY; LEUKEMOGENESIS; LUNG FIBROSIS; MOLECULAR BIOLOGY; MOUTH ULCER; MYALGIA; MYELOFIBROSIS; NAUSEA; NEUROTOXICITY; OPTIMAL DRUG DOSE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; SHIVERING; SIBLING; SIDE EFFECT; SINGLE DRUG DOSE; SKIN PIGMENTATION; SURVIVAL TIME; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT RESPONSE; WEIGHT REDUCTION; X IRRADIATION;

ANTINEOPLASTIC AGENTS; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 77957041355     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.07.001     Document Type: Article

References (65)

1. Bennett J.H. Case of hypertrophy of the spleen and liver in which death took place from the suppuration of the blood. Edinburgh Med Surg J 1845, 64:413-423.
2. Virchow R. Weisses Blut. Frorieps Notizen 1845, 36:151-156.
3. Donne A. De l'origine des globules du sang, de leur mode de formation, de leur fin. CR Acad Sci 1842, 4:366.
4. Virchow R. Die Leukämie. Gesammelte Abhandulungen Zur Wissenschaftlinchen Medizin 1856, 190-211. Meidinger, Frankfurt.
5. Bennett J.H. Leucocythaemia, or white cell blood in relation to the physiology and pathology of the lymphatic glandular system 1852, Sutherland and Knox, Edinburgh.
6. Geary C.G. The story of chronic myeloid leukaemia. Br J Haematol 2000, 110:2-11.
7. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497.
8. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
9. Abelson H.T., Rabstein L.S. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res 1970, 30:2213-2222.
10. de Klein A., Hagemeijer A., Bartram C.R., et al. bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 1986, 68:1369-1375.
11. Heisterkamp N., Stephenson J.R., Groffen J., et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983, 306:239-242.
12. Bernards A., Rubin C.M., Westbrook C.A., Paskind M., Baltimore D. The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Mol Cell Biol. 1987, 7:3231-3236.
13. Groffen J., Stephenson J.R., Heisterkamp N., et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
14. Goldman J.M., Grosveld G., Baltimore D., Gale R.P. Chronic myelogenous leukemia-the unfolding saga. Leukemia 1990, 4:163-167.
15. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
16. Konopka J.B., Watanabe S.M., Witte O.N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984, 37:1035-1042.
17. Canaani E., Gale R.P., Steiner Saltz D., et al. Altered transcription of an oncogene in chronic myeloid leukaemia. Lancet 1984, 1:593-595.
18. Shtivelman E., Lifshitz B., Gale R.P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985, 315:550-554.
19. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
20. Elefanty A.G., Hariharan I.K., Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990, 9:1069-1078.
21. Kelliher M.A., McLaughlin J., Witte O.N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 1990, 87:6649-6653.
22. Heisterkamp N., Jenster G., ten Hoeve J., et al. Acute leukaemia in bcr/abl transgenic mice. Nature 1990, 344:251-253.
23. Forkner C.E. Leukemia and allied disorders 1938, 126-135. Macmillan, New York.
24. Lissauer H. Zwei Falle von Leucaemie. Berl Klin Wochenshrift 1865, 2:403-404.
25. Conan Doyle A. Notes on a case of leucocythaemia. Lancet 1882, 25:490.
26. Galton D.A. Myleran in chronic myeloid leukaemia; results of treatment. Lancet 1953, 264:208-213.
27. Talpaz M., Kantarjian H.M., McCredie K., et al. Hematologic remission and cytogenetic improvement induced by recombinant human IFN alpha A in chronic myelogenous leukemia. N Engl J Med 1986, 314:1065-1069.
28. Goldman J.M., Baughan A.S., McCarthy D.M., et al. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet 1982, 2:623-625.
29. Fefer A., Cheever M.A., Thomas E.D., et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med 1979, 300:333-337.
30. Horowitz M., Rowlings P., Passweg J. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996, (Suppl 3):5-6.
31. Goldman J.M., Majhail N.S., Klein J.P., et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010, 28:1888-1895.
32. Guilhot F., Chastang C., Michallet M., et al. IFN alfa-2b combined with cytarabine versus IFN alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997, 337:223-229.
33. Baccarani M., Rosti G., de Vivo A., et al. A randomized study of IFN-alpha versus IFN-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002, 99:1527-1535.
34. Sokal J.E., Cox E.B., Baccarani M., et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
35. Hasford J., Pfirrmann M., Hehlmann R., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998, 90:850-858.
36. Allan N.C., Richards S.M., Shepherd P.C. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995, 345:1392-1397.
37. Sokal J.E., Baccarani M., Tura S., et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 1985, 66:1352-1357.
38. Report of the Medical Research Council's Working Party for Therapeutic Trials in Leukaemia. Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Br Med J 1968, 1:201-207.
39. Minot G., Buckman T., Isaacs R. Chronic myelogenous leukemia. JAMA 1924, 82:1493.
40. Jackson N., Shukri A., Ali K. Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br J Haematol 1993, 85:203-204.
41. Hehlmann R., Heimpel H., Hasford J., et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994, 84:4064-4077.
42. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994, 330:820-825. Italian Cooperative Group.
43. Ohnishi K., Ohno R., Tomonaga M., et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995, 86:906-916.
44. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997, 89:1616-1620. Chronic Myeloid Leukemia Trialists' Collaborative Group.
45. Silver R.T., Woolf S.H., Hehlmann R., et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999, 94:1517-1536.
46. Hochhaus A., Lin F., Reiter A., et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996, 87:1549-1555.
47. Kantarjian H.M., Smith T.L., O'Brien S., et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995, 122:254-261.
48. Bonifazi F., de Vivo A., Rosti G., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001, 98:3074-3081.
49. Mahon F.X., Bilhou-Nabera C., Cony-Makhoul P., et al. Molecular responder patients in chronic myeloid leukemia are mainly cured after treatment by interferon alpha. Blood 2003, 102:904a. [abstract].
50. Mahon F.X., Delbrel X., Cony-Makhoul P., et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002, 20:214-220.
51. Talpaz M., Kantarjian H.M., O'Brien S., Kurzrock R. The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. Baillieres Clin Haematol. 1997, 10:291-305.
52. Kluin-Nelemans H.C., Buck G., le Cessie S., et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 2004, 103:4408-4415.
53. Goldman J.M., Apperley J.F., Jones L., et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986, 314:202-207.
54. Mackinnon S., Hows J.M., Goldman J.M., et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol. 1990, 18:421-425.
55. Hansen J.A., Gooley T.A., Martin P.J., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998, 338:962-968.
56. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
57. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998, 339:1186-1193.
58. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997, 15:433-444.
59. Dazzi F., Szydlo R.M., Cross N.C., et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000, 96:2712-2716.
60. Kolb H.J., Schmid C., Buhmann R., Tischer J., Ledderose G. DLI: where are we now?. Hematology 2005, 10(Suppl 1):115-116.
61. Raiola A.M., Van Lint M.T., Valbonesi M., et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003, 31:687-693.
62. Anafi M., Gazit A., Gilon C., Ben Neriah Y., Levitzki A. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J Biol Chem. 1992, 267:4518-4523.
63. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2:561-566.
64. Deininger M.W.N., Goldman J.M., Lydon N.B., Melo J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997, 90:3691-3698.
65. Druker B.J., Lydon N.B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000, 105:3-7.